PROBABILITY OF NEOPLASTIC TRANSFORMATION IN DIFFERENT TYPES OF ENDOMETRIAL HYPERPLASIA
- Authors: DUMANOVSKAYA M.R1, CHERNUKHA G.E1, BURMENSKAYA O.V1, DONNIKOV A.E1, TROFIMOV D.Y.1
-
Affiliations:
- Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- Issue: No 8 (2013)
- Pages: 56-62
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247024
- ID: 247024
Cite item
Abstract
Keywords
Full Text
About the authors
M. R DUMANOVSKAYA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: m_dumanovskaya@oparina4.ru
G. E CHERNUKHA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: g_chernukha@oparina4.ru
O. V BURMENSKAYA
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: o_bourmenskaya@oparina4.ru
A. E DONNIKOV
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: a_ donnikov@oparina.ru
D. Yu TROFIMOV
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: d_troflmov@oparina4.ru
References
- Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2010; 21(2, прил. 1). 158с.
- Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., eds. SEER Cancer Statistics Review, 1975 2010, National Cancer Institute. Bethesda, MD. http://seer. cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013.
- rbo A., Arnes M., Hancke C., Vereide A.B., Pettersen I., Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol. Oncol. 2008; 111: 68—73.
- Reed S.D., Voigt L.F., Newton K.M., Garcia R., Allison H.K., Epplein M. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet. Gynecol. 2009; 113(3): 655—62.
- Allison K.H., Tenpenny E., Reed S.D., Swisher E.M., Garica R.L. Immunohistochemical markers in endometrial hyperplasia: Is there a panel with promise? A review. Appl. Immunohistochem. Mol. Morphol. 2008; 16(4): 329—43.
- Steinbakk A., Gudlaugsson E., Aasprong O.G., Skaland I., Malpica A., Feng W. et al. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am. J. Obstet. Gynecol. 2011; 204(4): 357; e1—12.
- Lacey J. V.Jr., Chia V.M. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009; 63: 39—44.
- Silverberg S.G., Kurman R.J., Nogales F., Mutter G.L., Kubik-Huch R.A., Tavassoli F.A. Tumors of the uterine corpus. Epithelial tumors and related lesions. In: Tavassoli F.A., Deville P., eds. WHO-classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003: 221—32.
- Upson K., Allison K.H., Reed S.D., Jordan C.D., Newton K.M., Swisher E.M. et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am. J. Obstet. Gynecol. 2012; 207(1): 36; e1—8.
- Власов Р.С. Клиническое значение метилирования генов-супрессоров опухолевого роста при патологических процессах эндометрия у женщин репродуктивного возраста: Автореф. дис.. канд. мед. наук. М.; 2011: 21—2.
- Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., Jackson R.S. 2nd. et al. NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 2004; 279; 47(19): 48930—40.
- Lv X.H., Chen J.W., Zhao G., Feng Z.Z., Yang D.H., Sun W.W. et al. N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J. Cancer Res. Clin. Oncol. 2012; 138(10): 1703—15.
- Lin Y.C., Chen C.C., Cheng C.J., Yang R.B. Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J. Biol. Chem. 2011; 286(30): 27039—47.
- Cheng C.J., Lin Y.C., Tsai M.T., Chen C.S., Hsieh M.C., Chen C.L., Yang R.B. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 2009; 69(8): 3634—41.
- Ghabreau L., Roux J.P., Niveleau A., Fontanière B., Mahe C., Mokni M., Frappart L. Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. Virchows Arch. 2004; 445(2): 129—34.
- Nunobiki O., Taniguchi E., Ishii A., Tang W., Utsunomiya H., Nakamura Y. et al. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. Pathol. Int. 2003; 53(12): 846—52.
- Baak J.P., Van Diermen B., Steinbakk A., Janssen E., Skaland I., Mutter G.L. et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum. Pathol. 2005; 36(5): 555—61.
- Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A. et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 2000; 92(11): 924—30.
- Kimura F., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y. et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J. Cancer Res. Clin. Oncol. 2004; 130(3): 161—8.
- Levicar N., Dewey R.A., Daley E., Bates T.E., Davies D., Kos J. et al. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 2003; 10: 141—51.
- Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C. et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006; 20: 543—56.
- Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007; 6(1): 60—4.
- Lankelma J.M., Voorend D.M., Barwari T., Koetsveld J., Van der Spek A.H., De Porto A.P. et al. Cathepsin L, target in cancer treatment? Life Sci. 2010; 86: 225—33.